Skip to main content

Table 3 Overview of AEs in all patients who received furmonertinib 160 mg monotherapy or combination therapy as subsequent treatment

From: Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy

Adverse events

Grade 1

Grade 2

Grade 3

Grade 4

 

n (%)

n (%)

n (%)

n (%)

General Disorders

    

 Fatigue

2 (7.1)

 

1 (3.6)

 

 Decreased appetite

2 (7.1)

 

1 (3.6)

 

Hematologic toxicity

    

 Leukopenia

3 (10.7)

1 (3.6)

 

1 (3.6)

 Anemia

5 (17.9)

2 (7.1)

  

 Decrased platelet count

   

1 (3.6)

Gastrointestinal toxicity

    

 Mucositis oral

  

1 (3.6)

 

 Diarrhea

 

1 (3.6)

  

Renal toxicity

    

 Increased serum creatinine

 

2 (7.1)

  

Metabolism disorders

    

 Hypocalcemia

  

1 (3.6)

 

Hepatobiliary toxicity

    

 Increased ALT/AST

4 (14.3)

 

1 (3.6)

 
  1. n number, AEs adverse events, ALT alanine aminotransferase, AST aspartate aminotransferase
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us